Skip to main content
SpringerLink
Log in

Antithyroid drug — induced agranulocytosis: Clinical experience with ten patients treated at one institution and review of the literature

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The frequency, predisposing factors and course of agranulocytosis (granulocytes <250/µl) secondary to antithyroid drugs were studied in a cohort of 1256 continously treated outpatients with hyperthyroidism during the 15 year period from 1973 to 1987. Two cases of agranulocytosis were detected; the frequency was 0.18% (95%-confidence intervals, 0.0–0.44%). This prevalence appers to be lower than reported in previous studies (up to 1.8%). For other adverse drug reactions, there was a clear-cut relationship to initial thiyonamide dose and to the body mass index; most reactions occurred during the first weeks of treatment. In addition, eight patients referred for thionamide drug-induced agranulocytosis were studied, and the following results obtained: Methimazole dose in patients with agranulocytosis was almost twice as in other patients (63.3±19.7 vs 34.3±29.7 mg daily) suggesting that this complication was related to dose. The interval between start of antithyroid drug treatment and first symptoms of agranulocytosis was 33 days (median; range, 23–55 days); hence, prolonged treatment beyond this period would appear relatively safe. Withdrawal of the causative agent and treatment of infection led to recovery of leukocyte counts within 15 days (median; range, 5–31 days). Two fatal outcomes were seen in referred patients. In one severely hyperthyroid patient with methimazole-induced agranulocytosis, recombinant human granulocyte/macrophage colony stimulating factor induced clinical and hematologic recovery within a few days of administration. In conclusion, agranulocytosis is the most severe side effect of antithyroid drugs. According to our results and a literature review, it occurs almost exclusively during the first ten weeks of treatment and is probably related to the drug dose. Physicians should be aware of this potentially serious complication particularly during this period. A reduction of traditionally prescribed thionamide doses seems quite possible and might lead to considerable reduction of adverse reactions. In severe cases, a trial of recombinant human granulocyte/macrophage colony stimulating factor should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Orgiazzi J. Management of Graves’ hyperthyroidism. Endocr. Metab. Clin. North Am. 76: 365, 1987.

    Google Scholar 

  2. Astwood E.B. Treatment of hyperthyroidism with thiourea and thiouracil. JAMA 122: 78, 1943.

    Article  CAS  Google Scholar 

  3. Fedotin M.S., Lefer L.G. Liver disease caused by propylthiouracil. Intern. Med. 735: 319, 1975.

    Google Scholar 

  4. Mihas A.A., Holley P., Koff K.S, Hirschowitz B.J. Fulminant hepatitis and lymphocyte sensitisation due to propylthioracil. Gastroenterology 70: 770, 1976.

    PubMed  CAS  Google Scholar 

  5. Safan M.M., Tatro D.S., Rudd P. Fatal propylthiouracil-induced hepatitis. Arch. Int. Med. 142: 838, 1982.

    Article  Google Scholar 

  6. Vitug A.C., Goldman J.M. Hepatotoxicity from antithyroid drugs. Horm. Res. 24: 229, 1985.

    Article  Google Scholar 

  7. Blom. H., Stalk J., Schreuder M.B., von Blomberg-van der Flier M. A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Arch. Int. Med. 745: 1513, 1985.

    Article  Google Scholar 

  8. McGravack T.H., Chevalley J. Untoward hemathologic responses to the antithyroid compounds. Am. J. Med. 77: 36, 1954.

    Article  Google Scholar 

  9. Bilezekian S.B., Laleli Y., Tsan M.F., Hodgkinson B.A., Lee S., McIntyre P.A. Immunological reactions involving leukocytes: III agranulocytosis induced by antithyroid drugs. John Hopkins Med. J. 138: 124, 1976.

    Google Scholar 

  10. Resove M.H. Agranulocytosis and antithyroid drugs. West Med. J. 726: 339, 1977.

    Google Scholar 

  11. Cooper D.S., Goldminz D., Levin A.A., Ladenson P.W., Daniels G.H., Molich M.E., Ridgeway E.C. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann. Int. Med. 98: 26, 1983.

    CAS  Google Scholar 

  12. Tajiri J., Noguchi S., Murakami T., Murakami N. Antithyroid drug-induced agranulocytosis. The usefullness of routine white blood cell count monitoring. Arch. Int. Med. 750: 621, 1990.

    Google Scholar 

  13. Meyer-Geßner M., Benker G., Olbricht T., Windeck R., Reiners C., Reinwein D. Nebenwirkungen der antithyreoidalen Therapie der Hyperthyreose. Eine Untersuchung an 1256 fortlaufend betreuten Patients. Dtsch. Med. Wschr. 114: 166, 1989.

    Google Scholar 

  14. Rosien U., Benker G., Brittinger G., Reinwein D. Agranulozytose-Behandlung mit rhGH-CSF. Dtsch. Med. Wschr. 114: 1861, 1989.

    PubMed  CAS  Google Scholar 

  15. Waller P.C. Measuring the frequency of adverse drug reactions. Br. J. Clin. Pharmac. 33: 249, 1992.

    Article  CAS  Google Scholar 

  16. Burrell C.D., Fraser R., Doniach D. The low toxicity of Carbimazole — a survey of 1046 patients. Brt. Med. J. 1: 1453, 1956.

    Article  CAS  Google Scholar 

  17. Krüskemper H.L. Nebenwirkungen thyreostatischer Arzneimmittel. Der. Internist. 9: 436, 1960.

    Google Scholar 

  18. Trotter W.R. The relative toxicity of antithyroid drugs. The Journal of New Drugs 333, 1962.

  19. Wiberg J.J., Natall F.Q. Methimazole toxicity from high doses. Ann. Int. Med. 77: 414, 1972.

    Article  PubMed  CAS  Google Scholar 

  20. Le Guerrier A.M., Lorcy Y., Allanic H. Les accidents imputables au Carbimazole dans le traitment de la maladie de Basedow. Ann. Endocrinol. (Paris) 45: 381, 1984.

    Google Scholar 

  21. Retsagi J., Kelly J.P., Kaufman D.W. Risk of agranulocytosis and asplastic anemia in relation to use of antithyroid drugs. Brit. Med. J. 297: 262, 1988.

    Article  Google Scholar 

  22. Werner M.C., Romaldini J.H., Bromberg N., Werner R.S., Farah C.S. Adverse effects related to thionamide drugs and their dose regimen. Am. J. Med. Sc. 297: 216, 1989.

    Article  CAS  Google Scholar 

  23. Edell S.L, Bartuska D.G. Aplastic anemia secondary to methimazole-a case report and review of the hematologic side effects. J. Am. Med. Wom. Assoc. 30: 412, 1975.

    PubMed  CAS  Google Scholar 

  24. Tamai H. Takaichi Y., Morita T., Komaki G., Mutsubayashi S., Kuma K., Walter jr. R.M., Kumagai L.F., Nataki S. Methimazole-induced agranulocytosis in Japanese patients with Graves’ disease. Clin. Endocrinol. (Oxf.) 30: 525, 1989.

    Article  CAS  Google Scholar 

  25. Hirata Y., Tasaka Y., Ogadiri R., Takei M., Kenbo T., Horino M. A new type of hypoglycemia with spontaneous insulin autoantibodies. Diabetes 26: 401, 1977.

    Google Scholar 

  26. Tahayama S., Hirata Y. Incidence of insulin autoimmune hypoglycemia in Japan during the three-year period from 1971–1981. Diabetes 32: Suppl. 150A, 1983.

    Google Scholar 

  27. Sanke T., Kondo M., Moriyama Y., Nanjo K., Iwo K., Miyamura K. Glucagon binding autoantibodies in a patient with hyperthyroidism treated with methimazole. J. Clin. Endocrinol. Metab. 57: 1140, 1983.

    Article  PubMed  CAS  Google Scholar 

  28. Melander A., Hallergren B., Rosendal-Helgesen S., Sjöberg A-K., Wahlin-Boll E. Comparative in-vitro effects and in vivo kinetics of antithyroid drugs. Eur. J. Clin. Pharmacol. 77: 295, 1980.

    Article  Google Scholar 

  29. Wing S.S., Fantus G. Adverse immunologic effects of antithyroid drugs. Can. Med. Assoc. J. 121, 1987.

  30. Cooper D.S., Daniels G.H., Ridgewayn E.C. Agranulocytosis and dose of methimazole. Ann. Int. Med. 101: 283, 1984.

    Article  PubMed  CAS  Google Scholar 

  31. Haynes R.C. Thyroid and antithyroid drugs. In: Goodman Gilman A., Rall T.W., Nies A.S., Taylor P. (Eds.) The Pharmacologicical Basis of Therapeutics. 8 ed. Pergamon press, New York 1990, p. 1361.

    Google Scholar 

  32. Heinrich B., Gross M., Goebel F.D. Methimazole-induced agranulocytosis and Granulocyte-colony stimulating factor. Ann. Int. Med. 111: 621, 1989.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Endocrinology, University of Essen, Hufelands 55, D-45122, Essen 1, Germany

    M. Meyer-Geßner, G. Benker, S. Lederbogen, T. Olbricht & D. Reinwein M.D.

Authors
  1. M. Meyer-Geßner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Benker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Lederbogen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Olbricht
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Reinwein M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer-Geßner, M., Benker, G., Lederbogen, S. et al. Antithyroid drug — induced agranulocytosis: Clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 17, 29–36 (1994). https://doi.org/10.1007/BF03344959

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344959

Key-words

Search

Navigation